Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Assessment of Significance of Novel Proteins in Breast Cancer Using Tissue Microarray Technology.

Mulrane L, Gallagher WM, O'Connor DP.

Methods Mol Biol. 2017;1501:311-325.

PMID:
27796961
2.

FKBPL: a marker of good prognosis in breast cancer.

Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T.

Oncotarget. 2015 May 20;6(14):12209-23.

3.

microRNAs: a new class of breast cancer biomarkers.

Mulrane L, Klinger R, McGee SF, Gallagher WM, O'Connor DP.

Expert Rev Mol Diagn. 2014 Apr;14(3):347-63. doi: 10.1586/14737159.2014.901153. Review.

PMID:
24649821
4.

A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.

Mulrane L, Gallagher WM, O'Connor DP.

Breast Cancer Res. 2014 Nov 18;16(6):467. doi: 10.1186/s13058-014-0467-x.

5.

miRNA dysregulation in breast cancer.

Mulrane L, McGee SF, Gallagher WM, O'Connor DP.

Cancer Res. 2013 Nov 15;73(22):6554-62. doi: 10.1158/0008-5472.CAN-13-1841. Epub 2013 Nov 7. Review.

6.

miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro.

Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG, Gallagher WM, O'Connor DP.

Clin Cancer Res. 2012 Dec 15;18(24):6702-13. doi: 10.1158/1078-0432.CCR-12-1420. Epub 2012 Oct 11.

7.

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW.

Mol Cancer. 2011 Oct 7;10:126. doi: 10.1186/1476-4598-10-126.

8.

Tissue microarrays and digital image analysis.

Ryan D, Mulrane L, Rexhepaj E, Gallagher WM.

Methods Mol Biol. 2011;691:97-112. doi: 10.1007/978-1-60761-849-2_6.

PMID:
20972749
9.

Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies.

Adler M, Hoffmann D, Ellinger-Ziegelbauer H, Hewitt P, Matheis K, Mulrane L, Gallagher WM, Callanan JJ, Suter L, Fountoulakis MM, Dekant W, Mally A.

Toxicol Lett. 2010 Jun 16;196(1):1-11. doi: 10.1016/j.toxlet.2010.03.018. Epub 2010 Apr 1.

PMID:
20362651
10.

Performance of novel kidney biomarkers in preclinical toxicity studies.

Hoffmann D, Adler M, Vaidya VS, Rached E, Mulrane L, Gallagher WM, Callanan JJ, Gautier JC, Matheis K, Staedtler F, Dieterle F, Brandenburg A, Sposny A, Hewitt P, Ellinger-Ziegelbauer H, Bonventre JV, Dekant W, Mally A.

Toxicol Sci. 2010 Jul;116(1):8-22. doi: 10.1093/toxsci/kfq029. Epub 2010 Jan 29.

11.

Automated image analysis in histopathology: a valuable tool in medical diagnostics.

Mulrane L, Rexhepaj E, Penney S, Callanan JJ, Gallagher WM.

Expert Rev Mol Diagn. 2008 Nov;8(6):707-25. doi: 10.1586/14737159.8.6.707. Review.

PMID:
18999923
12.

Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: an initial report from the PredTox group.

Mulrane L, Rexhepaj E, Smart V, Callanan JJ, Orhan D, Eldem T, Mally A, Schroeder S, Meyer K, Wendt M, O'Shea D, Gallagher WM.

Exp Toxicol Pathol. 2008 Aug;60(4-5):235-45. doi: 10.1016/j.etp.2007.12.004. Epub 2008 May 13.

PMID:
18479893

Supplemental Content

Loading ...
Support Center